Letter by Siasos et al Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the work by Jones et al1 comparing the efficiency of P2Y12 receptor inhibitors (clopidogrel versus ticagrelor) as antithrombotic regimens for long-term management in patients with symptomatic peripheral artery disease. Current knowledge in the field demonstrates that in patients with symptomatic peripheral artery disease with a history of limb revascularization, the optimal antithrombotic regimen for long-term management remains unknown.2 The authors found that ticagrelor did not reduce the primary composite end point of cardiovascular mortality, myocardial infarction, or ischemic stroke compared with clopidogrel in patients with peripheral artery disease and a …